Novel therapies in small cell lung cancer

摘要: Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor of the with a tendency to metastasize widely early in course disease. The VA staging system classifies disease into limited stage (LS) which confined one hemithorax and can be included radiation field or extensive (ES) extends beyond hemithorax. Current standard care concurrent chemoradiation for LS chemotherapy alone ES Only quarter patients will cured current treatments majority ultimately succumb their A very complex genetic landscape SCLC accounts its resistance conventional therapy high recurrence rate, however, at same time this complexity form basis effective targeted In recent years, several different therapeutic strategies agents have been under investigation potential role SCLC. Several them including EGFR TKIs, BCR-ABL mTOR inhibitors, VEGF inhibitors unsuccessful showing survival advantage others DNA repair cellular developmental pathway antibody drug conjugates (ADCs), as well immune vaccines, immunomodulators, checkpoint are being tested. So far, none these approved use phase I/II clinical trials, most promising strategy. article, we discuss novel currently available data